Changes in IVI’s Board of Trustees
June 30, 2017, Seoul, Korea - The International Vaccine Institute (IVI) today announced several changes in its Board of Trustees (BOT). Three new members will join the Board: Mr. Malcolm Sweeney, Dr. Chris Varma, and Dr. Ros-Mari Bålöw. Each will serve a three-year term, which will take effect on November 16, 2017.
“The new Board members bring diversity and a wealth of experience in areas ranging from global finance to entrepreneurship to international development and cooperation research,” said Dr. Jerome Kim, IVI Director General. “They bring leadership experience from their respective fields, and I am pleased they are joining our board.”
Malcolm Sweeney is a senior finance executive with extensive international experience who worked for major multinationals that include General Electric, Dun & Bradstreet and Novartis AG. He is currently the Director of Finance EMEA at NComputing UK Ltd., a California-based desktop virtualization company, and Member Nominated Director at IMS (UK) Pension Plan Trustee Company. He was previously the Non-Executive Director of Gentium S.p.A, a NASDAQ-listed biopharmaceutical company that developed and manufactured drugs for vascular diseases and cancer (acquired by Jazz Pharmaceuticals). Mr. Sweeney brings more than 40 years of experience in accounting (U.S. GAAP, IFRS), internal control, corporate governance, forecasting, budgeting, strategic planning, foreign exchange and cash/asset management and tax planning/compliance. He is a Chartered Accountant admitted to the Institute of England & Wales, and has a Bachelor of Science in Physics, Economics and Philosophy from the University of Exeter.
Chris Varma is an experienced entrepreneur and investor in the life sciences industry, and currently serves as an entrepreneur-in-residence at MPM Capital. He co-founded Blueprint Medicines, an oncology therapeutics company, and served as its president and chief executive officer prior to it going public in April 2015. Dr. Varma also co-founded Vision Medicines and serves as its president and chief executive officer. He also co-founded Warp Drive Bio while he was at Third Rock Ventures. He was a partner at Flagship Ventures, and during his last year at Flagship, he was the president and chief executive officer of Selventa (f.k.a. Genstruct). He previously served at Novartis AG, the U.S. Food and Drug Administration, and Millennium Pharmaceuticals. Dr. Varma holds a Ph.D. in Biomedical Sciences from the Harvard-MIT Division of Health Sciences & Technology, Master of Science in Management from Stanford University, and Master of Science and Bachelor of Science in Computer Science from Stanford University. He serves as a member of the Harvard Medical School (HMS) Therapeutics Advisory Council and the HMS Discovery Council and as a member of the board of directors of the Global Oncology Initiative.
Ros-Mari Bålöw will represent the Government of Sweden on the Board and succeeds Dr. Viveka Persson who ended her term as Board member on May 26, 2017. Dr. Bålöw was the Senior Research Officer at the Unit for Research Cooperation of the Swedish International Development Cooperation Agency (Sida) where she served as board member of WHO-based research programmes such as the Alliance for Health Policy and Systems Research (AHPSR), Human Reproduction Programme (HRP), and Tropical Disease Research (TDR). She was previously the Head of Development Cooperation at the Embassy of Sweden in Chisinau, Moldova and Senior Advisor, Social Affairs at the Embassy of Sweden in Kampala, Uganda. Dr. Bålöw was also seconded to the European Commission, DG Development as National Expert for Research for Development, in Brussels, Belgium. She served in various capacities at Uppsala University that include Deputy Director of International Science Programmes and Principal Lecturer in Radiochemistry, Section for Medical Biochemistry at the Medical Faculty. She holds a Ph.D (Dr.Med.Sci.) from the Department of Medical and Physiological Chemistry, Uppsala University and a Bachelor of Science in Chemistry and Microbiology from Uppsala University.
Dr. Persson who is from the Swedish National Agency for Higher Education was the Swedish representative on the Board since 2012 and also served as Vice Chair of the Board. George Bickerstaff was appointed as Board Vice Chair effectively immediately following Dr. Persson’s departure.
Mr. Bickerstaff has served on the Board since 2009 and is also chair of the Board’s Finance Committee. He is an internationally recognized expert in finance, healthcare and information technology. He has served at Novartis Pharma AG as its chief financial officer and held senior financial positions at IMS Health, Dun & Bradstreet and General Electric. He serves on numerous boards and is currently partner and managing director of M.M. Dillon & Co., an investment bank and financial advisory firm.
“We thank Viveka for her service and contributions to IVI as a board member,” said Prof. Adel Mahmoud, IVI Board Chair, “While it is with sadness that we see her go, we are excited about the new Board members, and I look forward to working with George as the incoming Vice Chair.”